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ABSTRACT
Familial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous disorder with three variants, FHH1 to FHH3. FHH1 is caused
by loss-of-function mutations of the calcium-sensing receptor (CaSR), a G-protein coupled receptor that predominantly signals via G-
protein subunit alpha-11 (Ga11) to regulate calcium homeostasis. FHH2 is the result of loss-of-functionmutations in Ga11, encoded by
GNA11, and to date only two FHH2-associated Ga11 missense mutations (Leu135Gln and Ile200del) have been reported. FHH3 is the
result of loss-of-function mutations of the adaptor protein-2 s-subunit (AP2s), which plays a pivotal role in clathrin-mediated
endocytosis. We describe a 65-year-old womanwho had hypercalcemia with normal circulating parathyroid hormone concentrations
andhypocalciuria, features consistentwith FHH, but shedidnot haveCaSRandAP2smutations.Mutational analysis of theGNA11gene
was thereforeundertaken, using leucocyteDNA, and this identiﬁedanovelheterozygousGNA11mutation (c.161C>T; p.Thr54Met). The
effect of the Ga11 variant was assessed by homology modeling of the related Gaq protein and by measuring the CaSR-mediated
intracellular calcium (Ca2þi) responses of HEK293 cells, stably expressing CaSR, to alterations in extracellular calcium (Ca
2þ
o) using ﬂow
cytometry. Three-dimensional modeling revealed the Thr54Met mutation to be located at the interface between the Ga11 helical and
GTPase domains, and to likely impair GDP binding and interdomain interactions. Expression of wild-type and the mutant Ga11 in
HEK293 cells stably expressingCaSRdemonstrate that theCa2þi responses after stimulationwithCa
2þ
o of themutantMet54Ga11 led to
a rightward shift of the concentration-response curve with a signiﬁcantly (p< 0.01) increasedmean half-maximal concentration (EC50)
value of 3.88mM (95% conﬁdence interval [CI] 3.76–4.01mM), when compared with the wild-type EC50 of 2.94mM (95% CI 2.81–
3.07mM) consistentwitha loss-of-function. Thus, our studieshave identiﬁeda thirdGa11mutation (Thr54Met) causingFHH2andreveal
a critical role for the Ga11 interdomain interface in CaSR signaling and Ca
2þ
o homeostasis. © 2016 The Authors. Journal of Bone and
Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR)
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Introduction
Familial hypocalciuric hypercalcemia (FHH) is characterizedby lifelong elevations of serum calcium concentrations in
association with normal or mildly raised serum parathyroid
hormone (PTH) concentrations in 80% of patients and low
urinary calcium excretion (urinary calcium-to-creatinine clear-
ance ratio<0.01) in 80% of patients.(1,2) FHHmay be inherited as
an autosomal dominant condition, and it is a genetically
heterogeneous disorder with three recognized variants, FHH1-3.
FHH1 (OMIM #145980) is caused by loss-of-function mutations
of the calcium-sensing receptor (CaSR), a G-protein coupled
receptor (GPCR)(3) that initiates activation of the G-protein
subunit aq/11 (Gaq/11) family, leading to enhancement of
phospholipase C (PLC) activity(4) and elevation of inositol 1,4,5-
trisphosphate (IP3) with rapid increase in intracellular calcium
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(Ca2þi) concentrations.
(5,6) These signal transduction events
allow the parathyroid CaSR to respond to small ﬂuctuations in
the prevailing extracellular calcium concentration ([Ca2þ]o) by
inducing alterations in PTH secretion through mechanisms that
likely involve effects on PTH mRNA stability(7) and PTH granule
exocytosis from the apical pole of parathyroid cells.(8) Moreover,
the kidney CaSR is considered to inﬂuence urinary calcium
excretion by modulating expression of claudin proteins that
mediate the paracellular reabsorption of calcium in the renal
thick ascending limb.(9,10) FHH2 (OMIM #145981) is the result of
loss-of-function mutations in the G-protein subunit-a11 (Ga11),
encoded by GNA11, and to date only two FHH2-associated Ga11
missense mutations have been reported (Fig. 1).(11) These two
FHH2-causing Ga11 mutations comprise a Leu135Gln missense
substitution and an in-frame isoleucine deletion at codon 200
(Ile200del), which are located in the Ga-subunit helical and
GTPase domains, respectively.(11) Both of these FHH2-causing
Ga11 mutations, which are predicted to disrupt G-protein
activation, have been shown to impair CaSR signal transduc-
tion.(11) FHH3 (OMIM #600740) is caused by loss-of-function
mutations of the adaptor protein-2 s-subunit (AP2s), encoded
by the AP2S1 gene. AP2s has a pivotal role in clathrin-mediated
endocytosis of GPCRs such as the CaSR, and to date more than
50 FHH3 patients with AP2s mutations, which are all missense
mutations involving the Arg15 residue (Arg15Cys, Arg15His and
Arg15Leu), have been reported.(12–16) Approximately 65% of
FHH patients will have a CaSR mutation, 5% an AP2s mutation,
<1% a Ga11 mutation, and the remaining30% of FHH patients
are considered to have involvement of a genetic abnormality
that remains to be identiﬁed. Here we report the identiﬁcation of
a novel Ga11 mutation in a patient with FHH in whom CaSR and
AP2s mutations had been previously excluded.
Materials and Methods
Case report
The patient, a 65-year-old woman of Indian origin, presented
with poor mobility and recurrent falls. She underwent
investigation and was found to have hypercalcemia (serum
adjusted-calcium concentration¼ 2.77mmol/L, normal range¼
2.20–2.60mmol/L) in association with normal serum concen-
trations of phosphate (0.85mmol/L; normal range¼ 0.70–
1.40mmol/L), creatinine (45mmol/L; normal range¼ 40–
130mmol/L), PTH (5.9 pmol/L; normal range¼ 1.0–7.0 pmol/L),
and serum25-hydroxyvitaminD (52 nmol/L; normal>50nmol/L).
Urinary calcium-to-creatinine clearance ratio was low at 0.01
(normal >0.02). These ﬁndings are consistent with a diagnosis
of FHH, although there appeared to be an absence of a family
history of hypercalcemia, based on the patient not having
knowledge of any relatives who suffered from symptomatic
hypercalcemia and the relatives not being available for medical
assessment. DNA sequence analyses of the CASR and AP2S1
genes had not identiﬁed any abnormalities. Informed consent
was obtained for the study using protocols approved by the
Multi-Centre Research Ethics Committee (UK) (MREC/02/2/93).
DNA sequence analysis
DNA sequence analyses of GNA11 exons 1–7 and their adjacent
splice sites (NM_002067) (Fig. 1) was performed using leucocyte
DNA and gene-speciﬁc primers (Sigma-Aldrich, St. Louis, MO,
USA), as previously reported.(11) Publicly accessible databases,
including dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/),
1000 genomes (http://browser.1000genomes.org), the National
Heart, Lung and Blood Institute (NHLBI) Exome Sequencing
Project (http://evs.gs.washington.edu/EVS/, EVS data release
ESP6500SI) representing the exomes of approximately 6500
individuals, and the Exome Aggregation Consortium (ExAC)
(exac.broadinstitute.org) representing exomes of 60,706 unre-
lated individuals, were examined for the presence of sequence
variants, and any potential pathogenic sequence abnormality
identiﬁed within the patient DNA was conﬁrmed by restriction
endonuclease analyses, as described.(12)
Protein sequence alignment and three-dimensional
modeling of Ga11 structure
Protein sequences of Ga11 paralogs were aligned using
ClustalOmega (http://www.ebi.ac.uk/Tools/msa/clustalo/).(17)
Ga11 three-dimensional modeling was undertaken using the
Fig. 1. Schematic representation of the genomic organization of the human GNA11 gene showing the locations of FHH2-causingmutations. The GNA11
gene consists of 7 exons with the start (ATG) and stop (TGA) codons located in exons 1 and 7, respectively. The GTPase domain (encoded by exon 1, 5’
portion of exon 2, 3’ portion of exon 4 and exons 5 to 7) is connected to the helical domain (encoded by the 3’ portion of exon 2, exon 3, and 5’ portion of
exon 4) by the linker 1 (L1) and linker 2 (L2) peptides. The locations of the P-loop (P) (red line), three ﬂexible switch regions (S1 to S3) (red line), and
the interdomain interface (comprising portions of the a1, aF, a5, b1, P-loop, and L1 peptide motifs) (blue line) are shown below the GNA11 exons. The
previously reported loss-of-function Leu135Gln and Ile200del mutations(11) are located in the helical and GTPase domains, respectively, whereas the
Thr54Met mutation (bold), identiﬁed by this study, is located at the interdomain interface. Coding regions are shaded gray and untranslated regions
are represented by open boxes.
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reported three-dimensional structure of Gaq in complex with
the small molecule inhibitor YM-254890 (Protein Data Bank
accession no. 3AH8).(18) The Gaq protein, which shares 90%
identity at the amino acid level with Ga11,
(11) was used because
crystal structures of Ga11 are not available. Molecular modeling
was performed using The PyMOL Molecular Graphics System
(Version 1.2r3pre, Schr€odinger, LL Pymol).(11)
Cell culture and transfection
Wild-type and mutant GNA11 (pBI-CMV2-GNA11) expression
constructs were generated as described,(11) and transiently
transfected into HEK293 cells stably expressing CaSR (HEK293-
CaSR)(12) using Lipofectamine 2000 (Life Technologies, Carlsbad,
CA, USA). The bidirectional pBI-CMV2 cloning vector was used
because it facilitated the co-expressionof Ga11 andGFP,
(11,12) and
site-directed mutagenesis was used to generate the mutant
GNA11 construct using the Quikchange Lightning Site-directed
Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) and
gene-speciﬁc primers (Sigma-Aldrich), as described.(19) Cells were
maintained in DMEM-Glutamax media (Thermo-Fisher, Waltham,
MA,USA)with10%fetal bovine serum(Gibco, Thermo-Fisher) and
400mg/mL geneticin (Thermo-Fisher) at 37°C, 5% CO2. Successful
transfectionwas conﬁrmed by visualizing GFP ﬂuorescence using
an Eclipse E400 ﬂuorescence microscope with a Y-FL Epiﬂuor-
escence attachment and a triband4,6-diamidino-2-phenylindole-
FITC-Rhodamine ﬁlter, and images captured using a DXM1200C
digital camera and NIS Elements software (Nikon, Tokyo,
Japan).(11–13) The expression of Ga11 and CaSR proteins was
also determined by Western blot analyses using anti-Ga11 (Santa
Cruz Biotechnology, Dallas, TX, USA), anti-GFP (Santa Cruz), anti-
calnexin (Millipore, Billerica, MA, USA) or anti-CaSR (AbCam,
Cambridge, UK) antibodies. The Western blots were visualized
using an Immuno-Star Western C kit (Bio-Rad, Hercules, CA, USA)
on a Bio-Rad Chemidoc XRSþ system.(11)
Intracellular calcium measurements
The Ca2þi responses of HEK293-CaSR cells expressing wild-type
or mutant Ga11 proteins were assessed by a ﬂow cytometry-
based assay, as reported.(11–13) In brief, HEK293-CaSR cells were
cultured in T75 ﬂasks and transiently transfected 24 hours later
with 16mg DNA.(11) Forty-eight hours after transfection, the cells
were detached, resuspended in calcium (Ca2þ)- and magnesium
(Mg2þ)-free Hanks’ buffered saline solution (HBSS), and loaded
with 1mg/mL Indo-1-acetoxymethylester (Indo-1-AM) for 1 hour
at 37°C. After removal of free dye, cells were resuspended in
Ca2þ- and Mg2þ-free HBSS and maintained at 37°C. Transfected
cells, in suspension, were stimulated by sequentially adding
Ca2þ to the Ca2þ- and Mg2þ-free HBSS to increase the [Ca2þ]o in
a stepwise manner from 0 to 15mM and then analyzed on a
MoFlo modular ﬂow cytometer (Beckman Coulter, Indianapolis,
IN, USA) by simultaneous measurements of GFP expression (at
525 nm), Ca2þi-bound Indo-1AM (at 410 nm), and free Indo-1AM
(ie, not bound to Ca2þi) (at 485 nm), using a JDSU Xcyte UV laser
(Coherent Radiation, Santa Clara, CA, USA), on each cell at each
[Ca2þ]o, as described
(11,12). The peak mean ﬂuorescence ratio
of the Ca2þi transient response after each individual stimulus
was measured using Cytomation Summit software (Beckman
Coulter) and expressed as a normalized response, as de-
scribed.(11,12) Nonlinear regression of concentration-response
curves was performed with GraphPad Prism (GraphPad, La Jolla,
CA, USA) using the normalized response at each [Ca2þ]o for each
separate experiment for the determination of EC50 (ie, [Ca
2þ]o
required for 50% of the maximal response) and Hill coefﬁcient
values. The maximal signaling response was measured as a fold-
change of the peak transient Ca2þi response to the basal Ca
2þ
i
response measured at 0mM [Ca2þ]o. The maximal signaling
responses for mutant Ga11 proteins were expressed as a
percentage of the wild-type Ga11 protein maximal signaling
response. The mean EC50 and Hill coefﬁcients obtained from
four separate transfection experiments were used for statistical
comparison by using the F-test, and alterations in maximal
signaling responses assessed using the Mann-Whitney U test.
Results
Identification of a novel Thr54Met Ga11 mutation in an
FHH proband
DNA sequence analyses of the GNA11 coding regions and
adjacent splice sites (Fig. 1) identiﬁed a heterozygous C-to-T
transition at nucleotide c.161, in the FHH patient (Figure 2A). This
C-to-T transition (ACG toATG) resulted in amissense substitution,
Thr54Met, of the Ga11 protein (Fig. 2B). The sequence alteration
also led to the gain of an NspI and loss of a BsiHKAI restriction
endonuclease site (Fig. 2B), which were used to conﬁrm the
presence of themutation in the patient (Fig. 2C, D). Bioinformatic
analyses using SIFT andMutationTasting software(20,21) predicted
the variant to be damaging and likely disease-causing (SIFT score
0, MutationTasting score 0.99). In addition, the absence of this
DNAsequence abnormality in>6500exomes fromtheNHLBI-ESP
cohort and>60,700 exomes from the ExAC cohort, together with
evolutionary conservation of the Thr54 residue in vertebrate
Ga-subunit paralogs (Fig. 3A), indicated that the Thr54Met
abnormality likely represented a pathogenic GNA11 mutation
rather than a benign polymorphic variant.
Structural characterization of the Thr54Met Ga11 mutant
protein
The Thr54Met mutation is located within the Ga11 a-1 helix
(Fig. 1 and Fig. 3A, B), which comprises part of the interface at
which the GTPase and helical domains interact to bind GDP and
GTP.(22) In contrast, the previously reported FHH2-causing
Iledel200 and Leu135Gln mutations,(11) which affect the GTPase
and helical domains of Ga11, respectively, are situated away
from the guanine-nucleotide binding site (Fig. 1 and Fig. 3B). The
Thr54 Ga11 residue is located next to the phosphate-binding
loop (P-loop) (Fig. 3A), which is a highly conserved nucleotide-
binding peptide motif that plays a critical role in binding
GDP.(23–25) Three-dimensional homology modeling of the Ga11
protein revealed the wild-type Thr54 residue to form polar
contacts with the ribose and b-phosphate moieties of GDP
within the interdomain interface (Fig. 3B, C) and to interact with
the a-F helix of the helical domain, which also mediates GDP
binding (Fig. 3C).(22) These ﬁndings are consistent with the
reported role of the a-1 helix as a structural hub that mediates
interactions between the GTPase and helical domains to ensure
GDP binding, thereby maintaining the Ga-subunit in an inactive
conformation.(26) The Ga11 Met54 mutant is predicted to disrupt
these interdomain contacts and alter GDP binding (Fig. 3C).
Functional characterization of the Thr54Met Ga11
mutant protein
To determine the effects of the predicted changes in Ga11
structure (Fig. 3B, C) on CaSR-mediated signaling, Ca2þi
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responses to alterations in [Ca2þ]o were assessed in HEK293-
CaSR cells that were transiently transfected with either the
pBI-CMV2 empty vector or pBI-CMV2 expressing the wild-type
(Thr54) or mutant (Met54) Ga11 proteins. The Ca
2þ
i responses of
cells expressing the Met54 Ga11 mutant were also compared
with cells transiently transfected with the reported FHH2-
associated Gln135 Ga11 mutant protein.
(11) Expression of CaSR,
Ga11 andGFPwas conﬁrmedby ﬂuorescencemicroscopy and/or
Western blot analyses (Fig. 4A, B). Calnexin was used as a loading
control in Western blot analyses, and Ga11 expression was
demonstrated to be similar in cells transiently transfected with
wild-type or mutant Ga11 proteins and greater than that of cells
transfected with the empty pBI-CMV2 vector (Fig. 4B). The Ca2þi
responses in wild-type and mutant Ga11-expressing cells
were shown to increase in a dose-dependent manner after
stimulation with increasing concentrations of Ca2þo between 0–
15mM. However, exposure to a signiﬁcantly greater [Ca2þ]o was
required to achieve half-maximal (EC50) Ca
2þ
i responses for cells
expressing either the Met54 or Gln135 mutant Ga11 proteins
compared with wild-type-expressing cells. (Fig. 4C, D). Thus, the
Met54 or Gln135 mutant-expressing cells showed rightward
shifts in the concentration-response curves, with signiﬁcantly
elevated mean EC50 values (p< 0.01) of 3.88mM (95% conﬁ-
dence interval [CI] 3.76–4.01mM) and 3.65mM (95% CI 3.57–
3.74mM), respectively, compared with 2.94mM (95% CI 2.81–
3.07mM) for wild-type expressing cells and consistent with
the Ga11 mutants leading to an impairment of CaSR signal
transduction (Fig. 4C, D). The Hill coefﬁcients did not signiﬁcantly
differ between wild-type and mutant Ga11-expressing cells
(Fig. 4E). However, cells expressing the Met54 mutant had
signiﬁcantly reduced maximal signaling responses compared
with cells expressing either wild-type or Gln135 mutant Ga11
proteins (p< 0.05) (Fig. 4F).
Discussion
Our studies have identiﬁed a novel heterozygous germline
GNA11 mutation in a patient with FHH, which resulted in an
impairment of Ca2þi signaling similar to the loss-of-function
previously reported for the FHH2-associated Leu135Gln and
Ile200del GNA11 mutations.(11) The Thr54Met mutation repre-
sents only the third loss-of-function GNA11 mutation to be
reported, and thus these ﬁndings provide further support for a
critical role of the Ga11 protein in parathyroid gland function
and Ca2þo homeostasis, and highlight the importance of GNA11
gene analyses in FHH patients that do not harbor CASR or AP2S1
mutations. The Thr54Met, Leu135Gln, and Ile200del loss-of-
function GNA11 mutations are all associated with a mild FHH
phenotype characterized by serum adjusted-calcium concen-
trations<2.80mmol/L, and these clinical ﬁndings are in keeping
with our in vitro studies that have shown FHH2-associated
Fig. 2. Identiﬁcation of a Thr54Met GNA11 mutation in a FHH proband. (A) DNA sequence analyses revealed a heterozygous C-to-T transition at
nucleotide c.161 (red arrow) within exon 2 of GNA11. (B) This sequence abnormality was predicted to lead to a missense amino acid substitution of Thr
to Met at codon 54, resulting in the loss of a BsiHKAI restriction endonuclease site (GAGCA/C) and gain of an NspI (GCATG/T) restriction endonuclease
site. (C) Restriction maps showing that BsiHKAI digestion would result in two products of 104 bp and 293 bp from the wild-type (WT) sequence but not
the mutant (m) sequence. In contrast, NspI digestion results in two products of 104 bp and 293 bp from the m sequence but not the WT sequence.
(D) Restriction endonuclease (RE) digest of PCR products of exon 2 of GNA11 demonstrating the heterozygous C-to-T transition and conﬁrming its
absence in two unrelated unaffected individuals (N1 andN2). S¼ sizemarker. For BsiHKAI RE digest themutant product (397 bp) andWTproduct (293 bp)
are shown; the WT product at 104 bp is not shown. For NspI RE digest the WT product (397 bp) and mutant product (293 bp) are shown; the mutant
product at 104 bp is not shown.
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mutations to induce only minor disturbances of CaSR signal
transduction.(11) Indeed, the FHH2mutants were associatedwith
around a 30% increase in the EC50 values of HEK293-CaSR cells
used in this study, whereas CaSR mutations leading to FHH1
generally cause a >50% increase in the EC50 value.
(3,27) The
milder shift in the Ca2þo set point of cells expressing FHH2-
associated Ga11 mutants indicates that the CaSR may promote
Ca2þi signaling by Ga11-independent mechanisms, such as via
the related Gaq protein. Indeed, reported studies that selectively
ablated Gaq and/or Ga11 in the parathyroid glands of mice have
highlighted the importance of both of these G-proteins for CaSR
function,(28,29) and in the setting of FHH1, CaSR mutations likely
impair Ca2þi responses via both Ga11 and Gaq, thus leading to a
greater loss-of-function than Ga11 mutations that cause FHH2.
The Ga11-subunit consists of a Ras-like GTPase domain that
binds GDP and GTP, and a smaller helical domain that acts as a
clasp to secure these bound guanine-nucleotides.(30) Three-
dimensional modeling indicated the Thr54Met mutation to be
located at the interdomain interface, which represents a highly
conserved and critical region containing the P-loop motif that
binds GDP(23,24) and also facilitates interactions between the
helical and GTPase domains that maintain Ga-subunits in an
inactive GDP-bound conformation.(22) The Thr54Met mutation
likely alters GDP binding, but in contrast to the other reported
Ga11 mutations (Arg60Cys, Arg60Leu, and Arg181Gln),
(11,31,32)
which are also located at the interdomain interface (Fig. 3B, C)
and cause Ga11 gain-of-function that is associated with the
clinical disorder of autosomal dominant hypocalcemia type-2
(ADH2), the Thr54Met Ga11 mutation causes loss-of-function
and FHH2. Thus, it seems that mutations involving the Ga11
interdomain interface may result in Ga11 loss-of-function or
gain-of-function. Crystal structures of Ga11 proteins are not
available to evaluate the structure-function effects of the
Thr54Met mutation at the interdomain interface; however, the
introduction of the mutant Met54 residue may sterically impair
G-protein function, as highlighted by a previous crystallography
study of a loss-of-function G-protein alpha-i (Gai) P-loop
mutation, which revealed the mutant Gai residue to sterically
hinder conformational changes of the ﬂexible “switch” regions
during Ga-subunit activation.(33) Moreover, interdomain inter-
face mutations that disrupt guanine-nucleotide binding may
also result in an “empty-pocket” mutant Ga-subunit that exerts
dominant-negative effects by binding and sequestering partner
GPCRs.(34) These ﬁndings may also help to provide an
explanation for the observed differences in the maximal
signaling responses of the FHH2-causing Met54 and Gln135
Ga11mutants (Fig. 4F). Thus, theMet54 Ga11mutant, but not the
Gln135 Ga11 mutant, led to a signiﬁcant reduction in the
maximal signaling response of CaSR-expressing cells (Fig. 4F),
even though both Ga11 mutants increase the Ca
2þ
o set point of
CaSR-expressing cells to a similar degree, as illustrated by their
EC50 values (Fig. 4D). The maximal signaling response of a GPCR
is inﬂuenced by the ability of the receptor to couple with its
cognate G-protein,(35) and thus it is possible that theMet54 Ga11
mutant impairs coupling and/or dissociation of Ga11 from
the CaSR by inﬂuencing guanine-nucleotide binding at the
Fig. 3. Predicted effects of the Thr54Met mutation on the Ga11 protein. (A) Multiple protein sequence alignment of residues contributing to the
interdomain interface of Ga-subunit paralogs. The wild-type Thr54 (T) and mutant Met54 (M) residues are shown in red. Conserved residues are shaded
gray. (B) Overall three-dimensional structure of the Ga11 protein. The helical (blue) and GTPase (green) domains are connected by the L1 and L2 peptides
(gray). The GTPase domain contains the P-loop (pink), which binds GDP (black) at the interdomain interface (comprising parts of a1, a5, aF, P-loop, L1,
and b1 peptide motifs). The reported Leu135Gln and Ile200del mutations(11) are shown in purple, and the Thr54Met mutation is shown in red. (C) Close-
up views of the Ga11 interdomain interface, which show the wild-type Thr54 residue, located in the GTPase domain, form polar contacts (hatched
black lines) with GDP and the Arg181 residue (yellow) of the helical domain aF helix. Substitution of the wild-type Thr54 residue with the mutant
Met54 residue (orange) is predicted to disrupt these polar contacts, thereby impairing interdomain interactions and the binding of GDP.
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interdomain interface,(34) whereas the Gln135 Ga11 mutant,
which is located in the Ga11 helical domain and not predicted to
inﬂuence CaSR-Ga11 coupling, may potentially diminish CaSR
signal transduction by inﬂuencing the interaction of Ga11 with
downstream effectors.(36)
In conclusion, we have identiﬁed a novel Ga11 loss-of-function
mutation, Thr54Met, that causes FHH2 and which provides new
insights into the critical role of the Ga11 interdomain interface in
CaSR signaling.
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Fig. 4. Functional characterization of wild-type and FHH2-associated mutant Ga11 proteins. (A) Fluorescence microscopy of HEK293 cells stably
expressing CaSR (HEK293-CaSR) and transiently transfected with wild-type (WT) or FHH2-associated mutant (Met54 and Gln135) pBI-CMV2-GNA11-GFP
constructs, or with vector only. GFP expression in these cells indicates successful transfection and expression by these constructs. Scale bar¼ 10 mm. (B)
Western blot analyses of whole-cell lysates using antibodies to CaSR, calnexin, Ga11, and GFP. Transient transfection of WT or FHH2-associated mutant
constructs resulted in overexpression of Ga11 when normalized to calnexin expression. (C) Concentration-response curves showing normalized Ca
2þ
i
response to changes in [Ca2þ]o of HEK293-CaSR cells transfected with WT or FHH2-associated Ga11 mutants. The Ca
2þ
i responses are shown as the
mean SEM of 4 independent transfections. The FHH2-associated Ga11 mutants (Met54 and Gln135) led to a rightward shift of the concentration-
response curves (blue and red, respectively) when compared with WT Ga11 (black), which harbors Thr and Leu residues at codons 54 and 135,
respectively. (D) The Met54 and Gln135 mutants (shaded bars) were associated with signiﬁcantly increased EC50 values compared with cells expressing
WT Ga11 (black bar). (E) The Hill coefﬁcients of the wild-type and mutant Ga11 proteins were similar (ie, not signiﬁcantly different). (F) The Met54 mutant
was associated with a signiﬁcantly reduced maximal signaling response compared with WT and mutant Gln135 Ga11 proteins. p< 0.05, p< 0.01.
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